Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ...
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...
What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 14.6% in the afternoon session after the company reported ...
Repligen (NASDAQ:RGEN) reported second-quarter 2026 revenue of $204 million, up 12% year over year on a reported basis and 13% organically, as demand for proteins, analytics products and recurring consumables supported growth. The company also raised its full-year organic revenue growth and adjusted
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 11.9% ...
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting results this Tuesday morning. Here’s what you need to know. Repligen bea...
What Happened? A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HC...
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...
Repligen (NASDAQ:RGEN) said it has signed a definitive agreement to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion, adding a cell therapy-focused platform that management said will expand Repligen’s exposure to one of the faster-growing areas of bioprocessing.
Presi
What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 7% in the morning session after investors reacted to the com...
Over the last six months, Repligen’s shares have sunk to $139.83, producing a disappointing 16% loss - a stark contrast to the S&P 500’s 9% gain. This might ...
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo...
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...
Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a co...
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services ind...
What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 2.9% in the afternoon session after RBC Capital resumed co...
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...
What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with servi...
